Cash Flow Statement

Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Others

Oramed Pharmaceuticals (ORMP) Change in Account Payables (2023 - 2024)

Oramed Pharmaceuticals' Change in Account Payables history spans 2 years, with the latest figure at $1.5 million for Q3 2024.

For Q3 2024, Change in Account Payables fell 10.42% year-over-year to $1.5 million; the TTM value through Sep 2024 reached $2.5 million, changed N/A, while the annual FY2023 figure was -$2.2 million, 491.76% down from the prior year.
Change in Account Payables reached $1.5 million in Q3 2024 per ORMP's latest filing, down from $2.2 million in the prior quarter.
In the past five years, Change in Account Payables ranged from a high of $2.2 million in Q2 2024 to a low of -$3.2 million in Q2 2023.